Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010093771 - COMBINATION VEGFR2 THERAPY WITH TEMOZOLOMIDE

Publication Number WO/2010/093771
Publication Date 19.08.2010
International Application No. PCT/US2010/023864
International Filing Date 11.02.2010
IPC
A61K 31/4188 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4188condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CPC
A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
A61K 38/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants
  • BRISTOL-MYERS SQUIBB COMPANY [US]/[US] (AllExceptUS)
  • CARVAJAL, Irvith, M. [VE]/[US] (UsOnly)
Inventors
  • CARVAJAL, Irvith, M.
Agents
  • HOLMES, Jennifer, K.
Priority Data
61/207,37611.02.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION VEGFR2 THERAPY WITH TEMOZOLOMIDE
(FR) THÉRAPIE VEGFR2 DE COMBINAISON AVEC LE TÉMOZOLOMIDE
Abstract
(EN)
The present disclosure relates to improved methods of treating neoplastic disorders by combining VEGFR2 specific inhibitor treatment with temozolomide. In particular, methods for treating glioblastoma with a combination of a VEGFR2 inhibitor and temozolomide are provided.
(FR)
La présente invention concerne des procédés améliorés de traitement de troubles néoplasiques en combinant un traitement avec un inhibiteur spécifique de VEGFR2 avec le témozolomide. La présente invention concerne en particulier des procédés pour traiter un glioblastome avec une combinaison d'un inhibiteur de VEGFR2 et de témozolomide.
Also published as
Latest bibliographic data on file with the International Bureau